SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health safety and infectious disease markets in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $93.78M |
| Gross Profit (TTM) | $40.85M |
| EBITDA | $21.21M |
| Operating Margin | -85.20% |
| Return on Equity | 11.00% |
| Return on Assets | 5.53% |
| Revenue/Share (TTM) | $1.31 |
| Book Value | $2.11 |
| Price-to-Book | 1.57 |
| Price-to-Sales (TTM) | 2.56 |
| EV/Revenue | 0.821 |
| EV/EBITDA | 4.42 |
| Quarterly Earnings Growth (YoY) | 1802.00% |
| Quarterly Revenue Growth (YoY) | -11.30% |
| Shares Outstanding | $71.72M |
| Float | $41.01M |
| % Insiders | 42.80% |
| % Institutions | 49.86% |
Volatility is currently expanding
Siga Technologies NASDAQ: SIGA reported a first-quarter loss as product deliveries remained minimal, but management said it expects a pickup in the second quarter tied to an international order and additional deliveries to the U.S. Strategic National Stockpile.
SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 7, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SIGA and any ticker you trade — then tracks every position and per-strategy win rate.
